Parabilis Medicines Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Parabilis Medicines Inc.
Former names
FOG Pharmaceuticals, INC.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Cambridge
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
PBLS
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001657677
EIN
47-4505725

Board of directors

Follow this board

Chief executives

Mathai Mammen · President & CEO
Since June 2026

Board connections

9 of this board's directors also sit on 32 other boards.

Network of Parabilis Medicines Inc.'s board connections Bicara Therapeutics Inc. Bicara Therapeutics In... Janux Therapeutics Inc. Janux Therapeutics Inc... Septerna Inc. Septerna Inc. Tyra Biosciences Inc. Tyra Biosciences Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. LENZ Therapeutics Inc. LENZ Therapeutics Inc. Mineralys Therapeutics Inc. Mineralys Therapeutics... Jake Simson Jake Simson Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Parabilis Medicines Inc.
Shared director Other board Same sector +16 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$441,418,109
14 purchases by 4 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jul 22, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +47,250 $29.77 $1,406,633
Jul 21, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +21,696 $27.96 $606,620
Jul 21, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +6,504 $29.17 $189,722
Jul 21, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +37,723 $30.00 $1,131,690
Jul 20, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +98,433 $27.13 $2,670,487
Jul 20, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +32,987 $27.72 $914,400
Jun 15, 2026 Alan Sebulsky Director Open-market purchase +5,000 $26.00 $130,000
Jun 15, 2026 Alan Sebulsky Director Open-market purchase +4,065 $27.10 $110,162
Jun 12, 2026 Alan Sebulsky Director Open-market purchase +8,435 $27.67 $233,396
Jun 11, 2026 Soleus Capital Group, LLC 10% owner Open-market purchase +375,000 $20.00 $7,500,000
Jun 11, 2026 RA Capital Nexus Fund III, L.P. Director Derivative conversion +6,556,740 — —
Jun 11, 2026 Edward M. Fitzgerald Director Derivative conversion +5,539 — —
Jun 11, 2026 Alan Sebulsky Director Open-market purchase +12,500 $20.00 $250,000
Jun 11, 2026 Alexis Borisy Director Derivative conversion +105,414 — —
Jun 11, 2026 Deerfield Mgmt HIF, L.P. 10% owner, Possible Member of 10% Group Derivative conversion +122,990 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.